These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
454 related articles for article (PubMed ID: 26232113)
1. Ovarian high-grade serous carcinoma with a noninvasive growth pattern simulating a serous borderline tumor. Imamura H; Ohishi Y; Aman M; Shida K; Shinozaki T; Yasutake N; Sonoda K; Kato K; Oda Y Hum Pathol; 2015 Oct; 46(10):1455-63. PubMed ID: 26232113 [TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic and Molecular Features of Paired Cases of Metachronous Ovarian Serous Borderline Tumor and Subsequent Serous Carcinoma. Chui MH; Xing D; Zeppernick F; Wang ZQ; Hannibal CG; Frederiksen K; Kjaer SK; Cope L; Kurman RJ; Shih IM; Wang TL; Vang R Am J Surg Pathol; 2019 Nov; 43(11):1462-1472. PubMed ID: 31343420 [TBL] [Abstract][Full Text] [Related]
3. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study. Vang R; Levine DA; Soslow RA; Zaloudek C; Shih IeM; Kurman RJ Int J Gynecol Pathol; 2016 Jan; 35(1):48-55. PubMed ID: 26166714 [TBL] [Abstract][Full Text] [Related]
4. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Singer G; Stöhr R; Cope L; Dehari R; Hartmann A; Cao DF; Wang TL; Kurman RJ; Shih IeM Am J Surg Pathol; 2005 Feb; 29(2):218-24. PubMed ID: 15644779 [TBL] [Abstract][Full Text] [Related]
5. Is Invasive Micropapillary Serous Carcinoma a Low-grade Carcinoma? Ohishi Y; Imamura H; Aman M; Shida K; Kaku T; Kato K; Oda Y Int J Gynecol Pathol; 2016 Jan; 35(1):56-65. PubMed ID: 26166721 [TBL] [Abstract][Full Text] [Related]
6. Somatic genetic alterations in synchronous and metachronous low-grade serous tumours and high-grade carcinomas of the adnexa. Murali R; Selenica P; Brown DN; Cheetham RK; Chandramohan R; Claros NL; Bouvier N; Cheng DT; Soslow RA; Weigelt B; McCluggage WG Histopathology; 2019 Mar; 74(4):638-650. PubMed ID: 30565721 [TBL] [Abstract][Full Text] [Related]
7. Characterization of TP53-wildtype tubo-ovarian high-grade serous carcinomas: rare exceptions to the binary classification of ovarian serous carcinoma. Chui MH; Momeni Boroujeni A; Mandelker D; Ladanyi M; Soslow RA Mod Pathol; 2021 Feb; 34(2):490-501. PubMed ID: 32801341 [TBL] [Abstract][Full Text] [Related]
8. Loss of p16INK4A expression in low-grade ovarian serous carcinomas. Schlosshauer PW; Deligdisch L; Penault-Llorca F; Fatemi D; Qiao R; Yao S; Pearl M; Yang Z; Sheng T; Dong J Int J Gynecol Pathol; 2011 Jan; 30(1):22-9. PubMed ID: 21131838 [TBL] [Abstract][Full Text] [Related]
9. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis. Dehari R; Kurman RJ; Logani S; Shih IeM Am J Surg Pathol; 2007 Jul; 31(7):1007-12. PubMed ID: 17592266 [TBL] [Abstract][Full Text] [Related]
10. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver. Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A; Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818 [TBL] [Abstract][Full Text] [Related]
11. Long-term Behavior of Serous Borderline Tumors Subdivided Into Atypical Proliferative Tumors and Noninvasive Low-grade Carcinomas: A Population-based Clinicopathologic Study of 942 Cases. Vang R; Hannibal CG; Junge J; Frederiksen K; Kjaer SK; Kurman RJ Am J Surg Pathol; 2017 Jun; 41(6):725-737. PubMed ID: 28248817 [TBL] [Abstract][Full Text] [Related]
12. KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma. Tsang YT; Deavers MT; Sun CC; Kwan SY; Kuo E; Malpica A; Mok SC; Gershenson DM; Wong KK J Pathol; 2013 Dec; 231(4):449-56. PubMed ID: 24549645 [TBL] [Abstract][Full Text] [Related]
13. Nicotinamide N-methyltransferase overexpression may be associated with poor prognosis in ovarian cancer. Harmankaya İ; Akar S; Uğraş S; Güler AH; Ezveci H; Aydoğdu M; Çelik Ç J Obstet Gynaecol; 2021 Feb; 41(2):248-253. PubMed ID: 32285726 [TBL] [Abstract][Full Text] [Related]
14. Determination of BRAF V600E (VE1) protein expression and BRAF gene mutation status in codon 600 in borderline and low-grade ovarian cancers. Sadlecki P; Walentowicz P; Bodnar M; Marszalek A; Grabiec M; Walentowicz-Sadlecka M Tumour Biol; 2017 May; 39(5):1010428317706230. PubMed ID: 28488545 [TBL] [Abstract][Full Text] [Related]
15. Low-Stage High-Grade Serous Ovarian Carcinomas: Support for an Extraovarian Origin. Morency E; Leitao MM; Soslow RA Int J Gynecol Pathol; 2016 May; 35(3):222-9. PubMed ID: 26630225 [TBL] [Abstract][Full Text] [Related]
16. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas]. Shao HL; Shen DH; Xue WC; Li Y; Yu YZ Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760 [TBL] [Abstract][Full Text] [Related]
17. Low-grade ovarian serous neoplasms (low-grade serous carcinoma and serous borderline tumor) associated with high-grade serous carcinoma or undifferentiated carcinoma: report of a series of cases of an unusual phenomenon. Boyd C; McCluggage WG Am J Surg Pathol; 2012 Mar; 36(3):368-75. PubMed ID: 22082603 [TBL] [Abstract][Full Text] [Related]
18. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas. Hsu CY; Bristow R; Cha MS; Wang BG; Ho CL; Kurman RJ; Wang TL; Shih IeM Clin Cancer Res; 2004 Oct; 10(19):6432-6. PubMed ID: 15475429 [TBL] [Abstract][Full Text] [Related]
19. Molecular subtypes of serous borderline ovarian tumor show distinct expression patterns of benign tumor and malignant tumor-associated signatures. Curry EW; Stronach EA; Rama NR; Wang YY; Gabra H; El-Bahrawy MA Mod Pathol; 2014 Mar; 27(3):433-42. PubMed ID: 23948749 [TBL] [Abstract][Full Text] [Related]
20. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. McCluggage WG Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]